Galectin Therapeutics : Corporate Presentation, May 2025

Published: 2025-05-12 08:17:11 ET GALT

Published on 05/12/2025 at 08:17

Focused Pipeline

Belapectin is a novel, potent, galectin-3 inhibitor with Fast Track Designation

Low toxicity as a carbohydrate-based molecule which is degraded by natural processes Patent protection through 2032

MASH Cirrhosis

Only company to exclusively focus on treatment for MASH cirrhosis and portal hypertension Significant efficacy observed in cirrhotic patients without varices

Promising NAVIGATE results at 18 month read out, ≥40% reduction in new varices vs placebo in

Oncology (Combination Therapy)

ITT; significantly lower incidence of new varices in per protocol population

Encouraging clinical response in difficult-to-treat cancers in combination with checkpoint inhibitor IND filed and approval to proceed received from FDA (Head & Neck cancer)

Over 25 years diverse experience in the

pharmaceutical research industry supporting global study operations from site to personnel management.

JESSICA KOPACZEWSKI

Senior Director, Clinical Operations

JOEL LEWIS

Chief Executive Officer & President

Financial executive with over 25 years of

management experience in a taxation, restructuring, acquisition, and private equity ventures.

JEFF KATSTRA

VP, CMC / Pharmaceutical Development

Highly experienced in pharmaceutical

development of novel formulations and medicines with advanced manufacturing techniques and bringing them to approval.

KHURRAM JAMIL, M.D.

Chief Medical Officer

Have two decades of expereince leading drug development across various stages of clinical trials in the pharmaceutical industry. Led multiple new drug application filings and secured approvals from several regulatory agencies.

Over 32 years of public and private company

experience including more than a decade of audit, tax and SEC registrant experience with a major accounting firm.

JACK W. CALLICUTT

Chief Financial Officer

Over 28 years of experience working in the

pharmaceutical industry in clinical data and trial management with 23 years as statistician.

SETH ZUCKERMAN

Senior Director, Biostatistics

EZRA LOWE, Ph.D.

VP, Clinical and Preclinical Pharmacology

Extensive experience in clinical pharmacology,

drug metabolism, and pharmacokinetics with various drug formats and across therapeutic areas, leading to 10 different global drug approvals.

Clinical Program

Development Stage

Drug

Indication

Discovery

Preclinical

Phase 1

Phase 2

Phase 3

Fibrosis

Belapectin

MASH Cirrhosis and Portal Hypertension

Cancer Immunotherapy (Combination therapy)

Belapectin + Keytruda

Melanoma + Head / Neck Cancer

Oral Galectin-3 Inhibitors

Discovery program to identify subcutaneous forms of carbohydrates and oral small molecules

Disclaimer

Galectin Therapeutics Inc. published this content on May 12, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 12, 2025 at 12:16 UTC.